Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone

Neuroscience

Volumn 203, Issue , 2012, Pages 170-179

  Mulcahy, P ^a   O'Doherty, A ^a   Paucard, A ^a   O'Brien, T ^a   Kirik, D ^b   Dowd, E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b LUND UNIVERSITY   (Sweden)

Author keywords

AAV synuclein; Animal models; Motor function; Parkinson's disease; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; PARVOVIRUS VECTOR; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ALPHA SYNUCLEINOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; MALE; NEURONS; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA;

EID: 84856440571     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.12.011     Document Type: Article

References (55)

1. Barneoud P., Parmentier S., Mazadier M., Miquet J.M., Boireau A., Dubédat P., Blanchard J.C. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 1995, 67(4):837-848.
2. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001, 2(5):325-334.
3. Becker G., Muller A., Braune S., Buttner T., Benecke R., Greulich W., Klein W., Mark G., Rieke J., Thumler R. Early diagnosis of Parkinson's disease. J Neurol 2002, 249(Suppl 3). III/4048.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3(12):1301-1306.
5. Biglan K.M., Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin Neurol 2007, 27(02):106. 112.
6. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000, 886(1-2):82-98.
7. Caboni P., Sherer T.B., Zhang N., Taylor G., Na H.M., Greenamyre J.T., Casida J.E. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol 2004, 17(11):1540-1548.
8. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 2008, 209(1):5-11.
9. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
10. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta 1998, 1364(2):222-235.
11. Dowd E., Monville C., Torres E.M., Dunnett S.B. The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 2005, 68(1-2):24-30.
12. Fitzsimmons D.F., Moloney T.C., Dowd E. Further validation of the corridor task for assessing deficit and recovery in the hemi-parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism. Behav Brain Res 2006, 169(2):352-355.
13. Grealish S., Xie L., Kelly M., Dowd E. Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Res Bull 2008, 77(5):312-319.
14. Grimm D., Kern A., Rittner K., Kleinschmidt A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998, 9(18):2745-2760.
15. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 1985, 62(3):389-394.
16. Hoglinger G.U., Féger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003, 84(3):491-502.
17. Hoglinger G.U., Lannuzel A., Khondiker M.E., Michel P.P., Duyckaerts C., Féger J., Champy P., Prigent A., Medja F., Lombes A., Oertel W.H., Ruberg M., Hirsch E.C. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005, 95(4):930-939.
18. Kieburtz K., Ravina B. Why hasn't neuroprotection worked in Parkinson's disease?. Nat Clin Pract Neurol 2007, 3(5):240-241.
19. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100(5):2884-2889.
20. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152(2):259-277.
21. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Björklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha synuclein in the nigrostriatal system. J Neurosci 2002, 22(7):2780-2791.
22. Klein A., Gidyk D.C., Shriner A.M., Colwell K.L., Tatton N.A., Tatton W.G., Metz G.A. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: a cautionary note. Behav Brain Res 2011, 222(1):33-42.
23. Lauwers E., Bequé D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., Casteels C., Vercammen L., Bockstael O., Nuttin B., Debyser Z., Baekelandt V. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging 2007, 28(2):248-257.
24. Lee C.S., Sauer H., Björklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72(3):641-653.
25. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009, 18(R1):R48-R59.
26. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004, 19(7):743-754.
27. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Alpha synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002, 99(16):10813-10818.
28. Meredith G.E., Sonsalla P.K., Chesselet M.-F. Animal models of Parkinson's disease progression. Acta Neuropathol 2008, 115(4):385-398.
29. Moreira C.G., Barbiero J.K., Ariza D., Dombrowski P.A., Sabioni P., Bortolanza M., Cunha C.D., Vital M.A., Lima M.M. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a New approach for an old neurotoxin. Neurotox Res 2011, 10.1007/s12640-011-9278-3.
30. Mulcahy P., Walsh S., Paucard A., Rea K., Dowd E. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience 2011, 181:234-242.
31. Norazit A., Meedeniya A.C., Nguyen M.N., Mackay-Sim A. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle. Brain Res 2010, 1360:119-129.
32. Olanow C.W., Yves A., Yoshi M., Alberto A., Bonucelli U., Philip D., De Justo Y., Oscar G., Mark G., Grandas F., Mark H., Ole H., Peter J., Katzenschlager R., William J.L., Peter L., Eldad M., Mena M.A., Michel P.P., Catherine M., Jose A.O., Werner P., Niall Q., Raisman-Vozari R., Ali H.R., Olivier R., Christina S., Fabrizio S. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004, 19(9):997-1005.
33. Olsson M., Nikkhah G., Bentlage C., Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995, 15(5 Pt 2):3863-3875.
34. Paille V., Picconi B., Bagetta V., Ghiglieri V., Sgobio C., Di Filippo M., Viscomi M.T., Giampà C., Fusco F.R., Gardoni F., Bernardi G., Greengard P., Di Luca M., Calabresi P. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 2010, 30(42):14182-14193.
35. Rajput A.H. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001, 8(2):95-100.
36. Ravenstijn P.G., Merlini M., Hameetman M., Murray T.K., Ward M.A., Lewis H., Ball G., Mottart C., de Ville de Goyet C., Lemarchand T., van Belle K., O'Neill M.J., Danhof M., de Lange E.C. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods 2008, 57(2):114-130.
37. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363(9423):1783-1793.
38. Santiago R.M., Barbieiro J., Lima M.M., Dombrowski P.A., Andreatini R., Vital M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(6):1104-1114.
39. Saravanan K.S., Sindhu K.M., Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005, 1049(2):147-155.
40. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39(5):777-787.
41. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003, 179(1):9-16.
42. Sindhu K.M., Banerjee R., Senthilkumar K.S., Saravanan K.S., Raju B.C., Rao J.M., Mohanakumar K.P. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 2006, 84(2):321-329.
43. Sindhu K.M., Saravanan K.S., Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005, 1051(1-2):25-34.
44. St Martin J.L., Klucken J., Outeiro T.F., Nguyen P., Keller-McGandy C., Cantuti-Castelvetri I., Grammatopoulos T.N., Standaert D.G., Hyman B.T., McLean P.J. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007, 100(6):1449-1457.
45. Swarnkar S., Singh S., Mathur R., Patro I.K., Nath C. A study to correlate rotenone induced biochemical changes and cerebral damage in brain areas with neuromuscular coordination in rats. Toxicology 2010, 272(1-3):17-22.
46. Swarnkar S., Singh S., Sharma S., Mathur R., Patro I.K., Nath C. Rotenone induced neurotoxicity in rat brain areas: a histopathological study. Neurosci Lett 2011, 501(3):123-127.
47. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011, 119(6):866-872.
48. Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 2008, 67(12):1149-1158.
49. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001, 500(3):105-108.
50. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
51. Warner T.T., Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S16-S23. discussion S23-S15.
52. Willis G.L., Kennedy G.A. The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease. Rev Neurosci 2004, 15(1):75-87.
53. Xiong N., Huang J., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 2009, 4(11):e7878.
54. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004, 91(2):451-461.
55. Zaitone S.A., Abo-Elmatty D.M., Shaalan A.A. Acetyl-l-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol Biochem Behav 2011, 100(3):347-360.